Want to see HK:1643 full AI Analyst Report?
1643 Stock Chart & Stats
HK$0.51
<HK$0.01(1.54%)
At close: 4:00 PM EST
HK$0.51
<HK$0.01(1.54%)
Day’s Range― - ―
52-Week RangeHK$0.49 - HK$3.26
Previous CloseN/A
Volume456.00K
Average Volume (3M)198.10K
Market Cap
HK$601.20M
Enterprise ValueHK$727.07
Total Cash (Recent Filing)HK$119.66M
Total Debt (Recent Filing)HK$1.20M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Mar 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.98%
Share Statistics
EPS (TTM)-0.06
Shares Outstanding720,000,000
10 Day Avg. Volume276,000
30 Day Avg. Volume198,100
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.61
Price to Sales (P/S)2.14
P/FCF Ratio-18.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces solvency risk and interest burden, giving the company financial flexibility to withstand weak demand and fund operational recovery without relying heavily on external financing.
Historical Earnings CapabilityEarlier strong profitability indicates the TCM business model has previously generated meaningful earnings, providing evidence that improved demand, product mix, or execution could restore operating performance over time.
Operating Cash FlowPositive operating cash flow during a loss-making year suggests the core business still converts some activity into cash, which can support continuity while management addresses declining revenue and profitability.
Bears Say
Persistent Revenue DeclineA multi-year revenue contraction signals weakening demand, distribution, or product competitiveness. If sustained, lower scale can limit investment capacity and create continuing pressure on profitability and market position.
Loss And Margin CompressionThe move into losses, combined with lower gross margins, indicates weaker pricing or product mix and negative operating leverage. Persistent compression would reduce the company’s ability to reinvest and rebuild growth.
Negative Free Cash FlowTwo consecutive years of negative free cash flow indicate weaker cash conversion or elevated spending needs. Continued cash burn could erode financial resilience despite the currently strong, low-debt balance sheet.
Modern Chinese Medicine Group Co. Ltd. News
1643 FAQ
What was Modern Chinese Medicine Group Co. Ltd.’s price range in the past 12 months?
Modern Chinese Medicine Group Co. Ltd. lowest stock price was HK$0.48 and its highest was HK$3.26 in the past 12 months.
What is Modern Chinese Medicine Group Co. Ltd.’s market cap?
Modern Chinese Medicine Group Co. Ltd.’s market cap is HK$601.20M.
When is Modern Chinese Medicine Group Co. Ltd.’s upcoming earnings report date?
Modern Chinese Medicine Group Co. Ltd.’s upcoming earnings report date is Mar 19, 2027 which is in 177 days.
How were Modern Chinese Medicine Group Co. Ltd.’s earnings last quarter?
Modern Chinese Medicine Group Co. Ltd. released its earnings results on Aug 28, 2026. The company reported -HK$0.041 earnings per share for the quarter.
Is Modern Chinese Medicine Group Co. Ltd. overvalued?
According to Wall Street analysts Modern Chinese Medicine Group Co. Ltd.’s price is currently Overvalued.
Does Modern Chinese Medicine Group Co. Ltd. pay dividends?
Modern Chinese Medicine Group Co. Ltd. pays a Notavailable dividend of HK$0.017 which represents an annual dividend yield of 2.98%. See more information on Modern Chinese Medicine Group Co. Ltd. dividends here
What is Modern Chinese Medicine Group Co. Ltd.’s EPS estimate?
Modern Chinese Medicine Group Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Modern Chinese Medicine Group Co. Ltd. have?
Modern Chinese Medicine Group Co. Ltd. has 720,000,000 shares outstanding.
What happened to Modern Chinese Medicine Group Co. Ltd.’s price movement after its last earnings report?
Modern Chinese Medicine Group Co. Ltd. reported an EPS of -HK$0.041 in its last earnings report. Following the earnings report the stock price went up 5.096%.
Which hedge fund is a major shareholder of Modern Chinese Medicine Group Co. Ltd.?
Currently, no hedge funds are holding shares in HK:1643
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Modern Chinese Medicine Group Co. Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
17.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.13%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Modern Chinese Medicine Group Co. Ltd.
As an investment holding company, Modern Chinese Medicine Group Co., Ltd. manufactures and distributes traditional Chinese pharmaceutical products, primarily targeting the middle-aged and elderly populations across the People's Republic of China. Its extensive product line provides treatments for a wide array of health issues, including qi deficiency, blood stasis, cardiovascular and cerebrovascular conditions, digestive and gastrointestinal ailments, gynecological problems, as well as disorders affecting the respiratory and nervous systems. Established in 1986, the enterprise maintains its principal offices in Chengde, China, and operates as a subsidiary of Modern Biotechnology Group Holdings Co., Ltd.
Technical Analysis
Tong Ren Tang Technologies Co
―
Wai Yuen Tong Medicine Holdings Limited
―
Lee's Pharmaceutical Holdings Limited
―
PuraPharm Corp. Ltd.
―
Pak Fah Yeow International Limited
―